Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Diagnostic Hybrids' rapid respiratory virus test

This article was originally published in Clinica

Executive Summary

Diagnostic Hybrids' test for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) has received 510(k) clearance from the US FDA. The D3 FastPoint L-DFA RSV/MPV identification kit identifies the viruses, which are the most common causes of lower respiratory infection in young children, within 25 minutes. It is the only FDA-cleared product that can detect both RSV and hMPV antigens simultaneously, the Athens, Ohio company claimed, adding that other rapid, point-of-care tests do not generally identify MPV. Like the firm's two other D3 FastPoint respiratory virus tests, the diagnostic uses monoclonal antibodies to detect the viruses in nasopharyngeal swabs, aspirates and washes.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel